Abhinav Deol, Salyka Sengsayadeth, Kwang Woo Ahn, Hai-Lin Wang, Mahmoud Aljurf, Joseph Harry Antin, Minoo Battiwalla, Martin Bornhauser, Jean-Yves Cahn, Bruce Camitta, Yi-Bin Chen, Corey S Cutler, Robert Peter Gale, Siddhartha Ganguly, Mehdi Hamadani, Yoshihiro Inamoto, Madan Jagasia, Rammurti Kamble, John Koreth, Hillard M Lazarus, Jane Liesveld, Mark R Litzow, David I Marks, Taiga Nishihori, Richard F Olsson, Ran Reshef, Jacob M Rowe, Ayman A Saad, Mitchell Sabloff, Harry C Schouten, Thomas C Shea, Robert J Soiffer, Geoffrey L Uy, Edmond K Waller, Peter H Wiernik, Baldeep Wirk, Ann E Woolfrey, Donald Bunjes, Steven Devine, Marcos de Lima, Brenda M Sandmaier, Dan Weisdorf, Hanna Jean Khoury, Wael Saber
BACKGROUND: Patients with FMS like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) have a poor prognosis and are referred for early allogeneic hematopoietic stem cell transplantation (HCT). METHODS: Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) were used to evaluate 511 adult patients with de novo AML who underwent HCT during 2008 through 2011 to determine whether FLT3 mutations had an impact on HCT outcomes. RESULTS: In total, 158 patients (31%) had FLT3 mutations...
October 2016: Cancer